Literature DB >> 15235585

Jak kinase activity is required for lymphoma invasion and metastasis.

Frank J M Opdam1, Marga Kamp, Rosalie de Bruijn, Ed Roos.   

Abstract

Jak tyrosine kinases are activated by interleukins and other growth factors, and promote survival and proliferation of cells in multiple tissues. These kinases are constitutively active in many hematopoietic malignancies and certain carcinomas. We have investigated whether Jak kinases play a role in lymphoma invasion and metastasis. Proliferation and survival of a highly metastatic T-lymphoma was made independent of its constitutively active Jak by expression of active forms of both STAT3 and PI3-kinase. Jak activity was then blocked by the isolated JH2 'pseudokinase' domain of Jak2. In vitro invasion was blocked by the JH2 domain, and the metastatic capacity of the JH2-expressing cells was much reduced. The Jak inhibitor AG490 inhibited invasion as well. Invasion and metastasis of these cells requires activation of the integrin LFA-1 by the CXCR4 chemokine receptor. We show that Jak kinases act downstream of LFA-1. We conclude that Jak kinase activity is essential for lymphoma invasion and metastasis, independent of its role in survival and proliferation, and independent of STAT and PI3K signaling. This indicates that Jak kinases contribute in multiple ways to the induction of malignant behavior.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15235585     DOI: 10.1038/sj.onc.1207887

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130.

Authors:  In Ae Seo; Hyun Kyoung Lee; Yoon Kyung Shin; Sang Hwa Lee; Su-Yeong Seo; Ji Wook Park; Hwan Tae Park
Journal:  Korean J Physiol Pharmacol       Date:  2009-04-30       Impact factor: 2.016

2.  Genetic reprogramming of tumor cells by zinc finger transcription factors.

Authors:  Pilar Blancafort; Emily I Chen; Beatriz Gonzalez; Sharon Bergquist; Andries Zijlstra; Daniel Guthy; Arndt Brachat; Ruud H Brakenhoff; James P Quigley; Dirk Erdmann; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

3.  IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines.

Authors:  Qinglin Liu; Gang Li; Ronghui Li; Jie Shen; Qiaowei He; Lin Deng; Cai Zhang; Jian Zhang
Journal:  J Neurooncol       Date:  2010-04-02       Impact factor: 4.130

4.  LAP2 is widely overexpressed in diverse digestive tract cancers and regulates motility of cancer cells.

Authors:  Hyun-Jung Kim; Sun-Hwi Hwang; Myoung-Eun Han; Sungmin Baek; Hey-Eun Sim; Sik Yoon; Sun-Yong Baek; Bong-Seon Kim; Jeong-Hwan Kim; Seon-Young Kim; Sae-Ock Oh
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

5.  Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.

Authors:  Tingting Feng; Wei Cao; Wanxiang Shen; Liang Zhang; Xinsheng Gu; Yang Guo; Hsiang-I Tsai; Xuewen Liu; Jian Li; Jingxuan Zhang; Shan Li; Fuyun Wu; Ying Liu
Journal:  Oncotarget       Date:  2017-01-03

6.  Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.

Authors:  M Pfeiffer; T N Hartmann; M Leick; J Catusse; A Schmitt-Graeff; M Burger
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

7.  CT findings predict survival of patients with peripheral T cell lymphoma: a preliminary study.

Authors:  Wenbin Yang; Sen Jiang; Jianbang Lin; Yangkang Li
Journal:  Radiol Oncol       Date:  2019-01-19       Impact factor: 2.991

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.